BR112016027818A2 - composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. - Google Patents

composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.

Info

Publication number
BR112016027818A2
BR112016027818A2 BR112016027818A BR112016027818A BR112016027818A2 BR 112016027818 A2 BR112016027818 A2 BR 112016027818A2 BR 112016027818 A BR112016027818 A BR 112016027818A BR 112016027818 A BR112016027818 A BR 112016027818A BR 112016027818 A2 BR112016027818 A2 BR 112016027818A2
Authority
BR
Brazil
Prior art keywords
virus
cells
blood plasma
plasma products
protein compositions
Prior art date
Application number
BR112016027818A
Other languages
English (en)
Portuguese (pt)
Inventor
Hoang Klen
Original Assignee
Rare Antibody Antigen Supply Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016027818(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rare Antibody Antigen Supply Inc filed Critical Rare Antibody Antigen Supply Inc
Publication of BR112016027818A2 publication Critical patent/BR112016027818A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112016027818A 2014-05-28 2015-05-28 composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. BR112016027818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (1)

Publication Number Publication Date
BR112016027818A2 true BR112016027818A2 (pt) 2017-10-24

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027818A BR112016027818A2 (pt) 2014-05-28 2015-05-28 composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.

Country Status (10)

Country Link
EP (1) EP3148574B1 (enExample)
JP (1) JP2017525752A (enExample)
CN (1) CN107106664A (enExample)
AU (1) AU2015266997A1 (enExample)
BR (1) BR112016027818A2 (enExample)
CA (1) CA2949994A1 (enExample)
ES (1) ES2878043T3 (enExample)
MX (1) MX2016015574A (enExample)
RU (1) RU2016151761A (enExample)
WO (1) WO2015184050A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
CN118903378A (zh) * 2024-03-19 2024-11-08 北京达尔文细胞生物科技有限公司 一种蛋白聚合物在治疗渐冻症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) * 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
JP5969458B2 (ja) * 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
SG185483A1 (en) * 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
TW201335181A (zh) * 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B

Also Published As

Publication number Publication date
ES2878043T3 (es) 2021-11-18
RU2016151761A3 (enExample) 2018-12-26
JP2017525752A (ja) 2017-09-07
WO2015184050A1 (en) 2015-12-03
CA2949994A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
CN107106664A (zh) 2017-08-29
EP3148574A4 (en) 2017-04-05
EP3148574A1 (en) 2017-04-05
RU2016151761A (ru) 2018-07-03
MX2016015574A (es) 2018-05-28
AU2015266997A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
PH12017500803A1 (en) Anti-pd-1 antibodies
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
NZ730803A (en) Methods for the preparation of ribosides
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201500536A1 (ru) Триазолопиразин
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
MX379275B (es) Polvo de coleopteros.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201201661A1 (ru) Новые аминопиразолохиназолины
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
TW201613885A (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements